Tumor necrosis factor-α monoclonal antibody, infliximab, used to manage severe sciatica: Point of view

Spine

Volumn 28, Issue 8, 2003, Pages 753-754

  Rydevik, Bjorn ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENTEEISM; BACKACHE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; FOLLOW UP; HUMAN; INTERVERTEBRAL DISK HERNIA; ISCHIALGIA; LEG PAIN; NERVE COMPRESSION; NERVE ROOT INJURY; NUCLEUS PULPOSUS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0037446961     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007632-200304150-00005     Document Type: Short Survey

References (5)

1. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 1993;18:1425-32.
2. Igatashi T, Kikuchi S, Shubajev V, et al. Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology: Molecular, histologic, and behavioural comparisons in rats. Spine 2000;25:2975-80.
3. Olmarker K, Larsson K. Tumor necrosis factor-alpha and nucleus pulposus-induced nerve root injury. Spine 1998;23:2538-44.
4. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: Possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001;26:863-9.
5. Mixter WB, Barr JS. Rupture of the intervertebral disk with involvement of the spinal canal. N Engl J Med 1934;211:210-15.